

# Compatibility, Stability, and Efficacy of Vancomycin Combined With Gentamicin or Ethanol in Sodium Citrate as a Catheter Lock Solution

Hospital Pharmacy  
2017, Vol. 52(10) 685–690  
© The Author(s) 2017  
Reprints and permissions:  
sagepub.com/journalsPermissions.nav  
DOI: 10.1177/0018578717726992  
journals.sagepub.com/home/hpx  


Yangjie Wei<sup>1</sup>, Joshua WonJoon Yang<sup>2</sup>, Sai HS. Boddu<sup>2</sup>,  
Rose Jung<sup>2</sup>, and Mariann D. Churchwell<sup>2</sup>

## Abstract

**Background:** Indwelling catheters deliver lifesaving medical treatments for many chronically ill patients but are frequently a source of infection. Treatment may include an antimicrobial agent(s) and anticoagulant solution dwelling within the catheter. In vitro determinations of solution compatibility and stability are necessary prior to use in patients. **Objective:** The aim of this study was to determine the physical compatibility, chemical stability, and antimicrobial activity of vancomycin (5 or 10 mg/mL) with gentamicin (1 mg/mL) or 40% ethanol in 4% sodium citrate lock solution over 72 hours. **Methods:** All solutions were prepared per manufacturer's instructions. Samples were studied under 4 conditions: (1) 25°C with light, (2) 25°C without light, (3) 37°C with light, and (4) 37°C without light. Physical compatibility and chemical stability were assessed at 0, 24, 48, and 72 hours. Antimicrobial susceptibility testing was conducted at 0 and 72 hours. All studies were carried out in triplicate. **Results:** All solution combinations under each condition remained patent from baseline to 48 hours. One solution combination of vancomycin (5 mg/mL) and ethanol (40% v/v) in 4% sodium citrate revealed a slight turbidity at 72 hours. Clarity and pH remained stable in all other solutions during the entire study period. Chemical compatibility and antibiotic activity ranged from 95% to 105% and 95% to 106% of initial baseline values, respectively, for all solutions under 4 storage conditions. **Conclusions:** All antibiotic-anticoagulant lock solutions were found to be physically, chemically, and microbiologically stable during the 72-hour study period except vancomycin (5 mg/mL) and ethanol (40% v/v) in 4% sodium citrate solution which showed slight turbidity at 72 hours.

## Keywords

catheter, vancomycin, ethanol, sodium citrate, compatibility

## Background

Indwelling catheters are necessary in the delivery of life-saving medical treatments and nutrition for many chronically ill patients. Unfortunately, long-term catheters are frequent sources of infection and present significant challenges when replacement of catheters is not readily feasible.<sup>1,2</sup> Antimicrobial lock solutions have been shown to be effective in the management of catheter-related bloodstream infections (CRBSIs) when used in conjunction with systemic antibiotics.<sup>3</sup> Catheter flush or antimicrobial lock solutions are also recommended for prophylaxis in patients with long-term catheters with recurrent CRBSIs.<sup>1,2</sup>

Catheter lock solutions containing an antimicrobial agent and/or anticoagulant solution may be used to eradicate bacteria from the catheter lumen increasing catheter salvage rates. Empiric antimicrobial agents included in catheter lock

solutions should target gram-positive organisms, a common pathogen responsible for the majority of catheter-related infections.<sup>1,2</sup> In addition to antimicrobial agents such as vancomycin and gentamicin, ethanol has been used to eradicate various pathogens when combined in catheter lock solutions. Heparin is a commonly used anticoagulant to maintain patency but sodium citrate, an ion chelator, has also been used. A previous study has shown compatibility when cefepime or ethanol is combined with sodium citrate.<sup>4</sup>

<sup>1</sup>The University of Kansas, Lawrence, KS, USA

<sup>2</sup>The University of Toledo, OH, USA

### Corresponding Author:

Mariann D. Churchwell, Associate Professor, Department of Pharmacy Practice, College of Pharmacy & Pharmaceutical Sciences, The University of Toledo, 3000 Arlington, MS 1013, Toledo, OH 43614, USA.  
Email: mariann.churchwell@utoledo.edu

**Table 1.** Lock Solution Composition.

Samples	Compositions			
	Vancomycin stock (50 mg/mL)	Gentamicin stock (40 mg/mL)	Ethanol	Sodium citrate 4% solution
Vancomycin 5 mg/mL	10%	—	—	90%
Vancomycin 5 mg/mL with 40% ethanol	10%	—	40%	50%
Vancomycin 5 mg/mL with gentamicin 1 mg/mL	10%	2.5%	—	87.5%
Vancomycin 10 mg/mL	20%	—	—	80%
Vancomycin 10 mg/mL with 40% ethanol	20%	—	40%	40%
Vancomycin 10 mg/mL with gentamicin 1 mg/mL	20%	2.5%	—	77.5%

Currently, most hospitals compound catheter lock solutions based on published in vitro solution compatibility and stability studies and small in vivo studies.<sup>5-7</sup> Compatibility and stability study data of the solutions are necessary prior to patient administration. Alternative additives such as ethanol and sodium citrate should be evaluated with traditional antimicrobial agents to minimize toxicity, adverse events, or resistance to traditional agents.<sup>8,9</sup>

## Objective

The purpose of this study was to determine the in vitro physical stability, chemical compatibility, and antimicrobial activity for the combination of gentamicin, vancomycin, ethanol, and sodium citrate over 72 hours.

## Materials and Methods

Six different admixtures containing sodium citrate and vancomycin with ethanol or gentamicin were evaluated for compatibility, stability, and efficacy over 72 hours with or without light exposure at room and body temperatures. All solutions were prepared from commercially available products using aseptic technique in a laminar-airflow hood.

## Preparation and Storage of Lock Solutions

Catheter lock solutions were prepared by mixing vancomycin (final concentration of 5 or 10 mg/mL) with either gentamicin (final concentration of 1 mg/mL) or ethanol 40% in 4% sodium citrate solution (Table 1). Each lock solution was evaluated under the following conditions: room temperature (25°C) with light and without light, and body temperature (37°C) with light and without light. Samples were obtained at 0, 24, 48, and 72 hours and evaluated for physical compatibility, chemical stability, and microbiological susceptibility. Each study was carried out in triplicate. After analyzing the physical compatibility and chemical stability, all samples were passed through a 0.2- $\mu$ m syringe filter (Thermo Nalgene, Rochester, NY, USA) and stored at -80°C for antimicrobial susceptibility testing.

## Evaluation of Physical Compatibility

Physical compatibility of each admixture was examined by measuring pH and clarity. The pH was measured using a pH meter (Accumet AB15; Fisher Scientific, Pittsburgh, Pennsylvania), and a change ( $\Delta$ pH) > 0.1 was considered significant. Clarity was evaluated by visual inspection against black and white backgrounds and graded from 0 to 4 with 0 indicating no precipitation. Clarity was further analyzed using an ultraviolet-light-visible spectrophotometer (Genesys 6; Thermo Scientific, Waltham, MA, USA) at 660 nm. An absorbance value  $\geq 0.010$  absorbance units (AU) was considered turbid.

## Evaluation of Chemical Stability

A UV spectrophotometric method was developed for simultaneous estimation of vancomycin and gentamicin.<sup>10</sup> This method involved the measurement of absorbance of vancomycin and gentamicin at wavelengths of 280 nm ( $\lambda_{\max}$  of vancomycin) and 255 nm ( $\lambda_{\max}$  of gentamicin) using a UV-Vis Spectrophotometer (Agilent 8453 UV-Visible Spectroscopy System, Waldbronn, Germany). Unknown concentrations of vancomycin and gentamicin were calculated using the following equations:

$$C_{\text{vancomycin}} = \left\{ \left[ (Abs_{255} \times 11) - (Abs_{280} \times 47) \right] - 0.42 \right\} / 0.1569,$$

$$C_{\text{gentamicin}} = \left\{ \left[ \frac{(Abs_{255} \times 39) - (Abs_{280} \times 24)}{(Abs_{280} \times 24)} \right] - 0.3012 \right\} / 0.1569,$$

where  $C_{\text{vancomycin}}$  and  $C_{\text{gentamicin}}$  represented concentrations of vancomycin and gentamicin ( $\mu$ g/mL) in admixtures, respectively;  $Abs_{255}$  and  $Abs_{280}$  represented absorbance of mixture solution at 255 nm and 280 nm, respectively. Accuracy of the analytical method was evaluated by determining the recovery percentage of samples with known drug concentrations. Assay validation demonstrated that the recovery for vancomycin and gentamicin was between 98.6% and 102.8% and 96.9% and 100.5%, respectively. The intraday and interday coefficients of variation of vancomycin and gentamicin were satisfactory

**Table 2.** Calibration Curves of Vancomycin and Gentamicin at 280 nm and 255 nm.

Component	Concentration range, $\mu\text{g/mL}$	Calibration curve at 280 nm	$R^2$	Calibration curve at 255 nm	$R^2$
Vancomycin	15.625-500	$y = 0.0039x + 0.0107$	1	$y = 0.0024x + 0.0133$	0.9999
Gentamicin	12.5-400	$y = 0.0011x + 0.0021$	1	$y = 0.0047x + 0.0023$	1

because the relative standard deviations of the drug concentrations did not exceed 0.27%. A different set of calibration standards ranging from 15.625 to 250  $\mu\text{g/mL}$  were prepared for analyzing vancomycin from admixtures containing ethanol at 280 nm. A straight line ( $y = 0.0042x - 0.0031$ ) was obtained with a correlation coefficient ( $r^2$ ) value of 0.9999 (Table 2). Chemical stability of drugs in admixtures was assessed by measuring the drug content at 0, 24, 48, and 72 hours.

### Antimicrobial Susceptibility Testing

Stability of antimicrobial activity was determined by Kirby-Bauer disk diffusion method according to the guidelines established by the Clinical and Laboratory Standards Institute (CLSI).<sup>11</sup> To determine antibacterial activities of gentamicin and vancomycin, reference strains of *Escherichia coli* ATCC 25922 and *Staphylococcus aureus* ATCC 25923 were used, respectively. Because a number of samples contained both vancomycin and gentamicin, a clinical strain of *S aureus* resistant to gentamicin but susceptible to vancomycin was obtained from the University of Toledo Medical Center and was evaluated in all samples containing vancomycin with and without gentamicin.

The Mueller-Hinton agar (MHA) was prepared according to the manufacturer's instructions. After autoclaving, the agar was poured into flat bottomed petri dishes to give uniform depths of about 4 mm. The agar was allowed to cool to room temperature and, unless used on the same day, stored in the refrigerator (2°C-8°C). Bacterial colonies from overnight growth were added to normal saline and adjusted turbidity to equal to a 0.5 McFarland standard ( $1.5 \times 10^8$  colony-forming units/mL). The surface of MHA plates was inoculated using a sterile swab that was dipped into the adjusted bacterial suspension and streaked over the surface of the agar plates.

Antimicrobial susceptibility test disks containing gentamicin 10  $\mu\text{g}$  and vancomycin 30  $\mu\text{g}$  (BBL Sensi-Discs; Becton Dickinson Biosciences, Franklin Lakes, NJ, USA) were used. In addition, blank disks were impregnated with required amounts of sample equivalent to the potency of the standard gentamicin and vancomycin disks calculated based on initial concentrations of vancomycin and gentamicin. The standard and the sample disks were applied on the surface of agar plates manually using sterile forceps in such a way that each disk was at least 24 mm away from other disks and from the edge of the petri plate to avoid contamination. The plates were incubated in air at 35°C to 37°C for 24 hours before measuring the zones of inhibition. All the tests were conducted in triplicate.

Antimicrobial activity was calculated by comparing the zones of inhibition at 72 hours to the baseline values and presented as a percentage of the baseline zones of inhibition. These values were then compared using one-way analysis of variance (ANOVA), and when statistically significant results were obtained, Tukey post hoc test was conducted. A  $P$  value  $\leq 0.05$  was considered statistically significant. All statistical tests were conducted using IBM SPSS Statistics 21 Software (IBM Corp, Armonk, New York).

## Results

### Physical and Chemical Stability of Lock Solutions

At baseline, 24 hours, and 48 hours, all solution combinations containing vancomycin (5 or 10 mg/mL) with either gentamicin (1 mg/mL) or ethanol (40%) in 4% sodium citrate under 4 different conditions remained visually clear, exhibiting no precipitate or turbidity (all solutions were graded 0 at each time point). Over 72 hours, all solutions except one combination maintained clarity measured by spectrophotometric absorbance. At 48 hours, the admixture containing vancomycin (5 mg/mL) and ethanol (40% v/v) in a 4% sodium citrate solution stored under 4 different conditions did not display any turbidity but at 72 hours; this admixture showed an absorbance value  $>0.010$  AU which indicated turbidity.

The pH of each admixture under 4 conditions maintained pH within the acceptable margins during the 72-hour study period. Chemical stability of gentamicin and vancomycin was assessed and the mean concentrations ranged between 95% and 105% of initial concentrations after 72 hours (Table 3).

### Antimicrobial Susceptibility Testing

The average antimicrobial activity based on zones of inhibition is reported in Table 4. The mean antimicrobial activity of vancomycin against *S aureus* ranged from 95% to 106% of baseline zones of inhibition after 72 hours. The average activity of gentamicin against *E coli* was 99% to 104% of the baseline after 72 hours. Overall, no significant change was observed for all 6 combinations of lock solutions under the 4 different storage conditions ( $P > 0.05$ ).

## Discussion

Catheter lock solutions containing an antimicrobial agent and anticoagulant solution have been used to reduce CRBSIs and maintain patency. Although the most widely

**Table 3.** Physical and Chemical Compatibility of Sodium Citrate and Vancomycin With Ethanol or Gentamicin Under Different Storage Conditions at 72 Hours.

Sample and storage conditions	Change in pH, mean $\pm$ SD	Clarity, <sup>a</sup> mean $\pm$ SD	Percentage of initial vancomycin concentration, mean $\pm$ SD	Percentage of initial gentamicin concentration, mean $\pm$ SD
Vancomycin 5 mg/mL				
25°C without light	0.089 $\pm$ 0.014	0.003 $\pm$ 0.0005	104.0 $\pm$ 0.2	NA
25°C with light	0.07 $\pm$ 0.010	0.003 $\pm$ 0.0005	104.1 $\pm$ 0.2	NA
37°C without light	0.08 $\pm$ 0.014	0.004 $\pm$ 0.0006	104.7 $\pm$ 0.2	NA
37°C with light	0.089 $\pm$ 0.010	0.004 $\pm$ 0.0006	104.6 $\pm$ 0.3	NA
Vancomycin 5 mg/mL with 40% ethanol				
25°C without light	0.020 $\pm$ 0.014	0.015 $\pm$ 0.0015	100.9 $\pm$ 0.2	NA
25°C with light	0.0207 $\pm$ 0.014	0.016 $\pm$ 0.0005	101.0 $\pm$ 0.2	NA
37°C without light	0.05 $\pm$ 0.014	0.017 $\pm$ 0.0006	101.5 $\pm$ 0.2	NA
37°C with light	0.030 $\pm$ 0.014	0.016 $\pm$ 0.0012	101.3 $\pm$ 0.2	NA
Vancomycin 5 mg/mL with gentamicin 1 mg/mL				
25°C without light	0.00 $\pm$ 0.010	0.003 $\pm$ 0.0005	99.0 $\pm$ 0.5	99.0 $\pm$ 0.5
25°C with light	0.00 $\pm$ 0.022	0.003 $\pm$ 0.0005	97.5 $\pm$ 0.6	96.2 $\pm$ 0.9
37°C without light	0.00 $\pm$ 0.010	0.005 $\pm$ 0.0006	98.2 $\pm$ 0.3	96.3 $\pm$ 0.2
37°C with light	0.020 $\pm$ 0.014	0.004 $\pm$ 0.0008	97.3 $\pm$ 0.2	96.1 $\pm$ 0.3
Vancomycin 10 mg/mL				
25°C without light	-0.030 $\pm$ 0.014	0.003 $\pm$ 0.0000	100.8 $\pm$ 0.3	NA
25°C with light	-0.030 $\pm$ 0.014	0.003 $\pm$ 0.0010	100.8 $\pm$ 0.3	NA
37°C without light	-0.020 $\pm$ 0.014	0.002 $\pm$ 0.0000	100.0 $\pm$ 0.1	NA
37°C with light	-0.010 $\pm$ 0.014	0.002 $\pm$ 0.0000	100.2 $\pm$ 0.2	NA
Vancomycin 10 mg/mL with 40% ethanol				
25°C without light	0.030 $\pm$ 0.022	0.008 $\pm$ 0.0001	97.2 $\pm$ 0.3	NA
25°C with light	0.020 $\pm$ 0.014	0.007 $\pm$ 0.0001	96.8 $\pm$ 0.2	NA
37°C without light	0.030 $\pm$ 0.014	0.006 $\pm$ 0.0001	97.0 $\pm$ 0.1	NA
37°C with light	0.030 $\pm$ 0.014	0.005 $\pm$ 0.0001	97.2 $\pm$ 0.0	NA
Vancomycin 10 mg/mL with gentamicin 1 mg/mL				
25°C without light	-0.010 $\pm$ 0.014	0.002 $\pm$ 0.0001	100.1 $\pm$ 0.1	98.8 $\pm$ 0.6
25°C with light	0.010 $\pm$ 0.014	0.001 $\pm$ 0.0001	100.0 $\pm$ 0.1	99.0 $\pm$ 0.5
37°C without light	-0.030 $\pm$ 0.014	0.002 $\pm$ 0.0000	100.3 $\pm$ 0.3	95.6 $\pm$ 0.5
37°C with light	-0.030 $\pm$ 0.014	0.001 $\pm$ 0.0000	100.1 $\pm$ 0.2	95.2 $\pm$ 0.3

Note. NA = not applicable.

<sup>a</sup>Clarity assessed by spectrophotometric absorbance at 660 nm.

used catheter lock solution is unfractionated heparin, there are safety concerns related to its use such as the risk of bleeding due to leakage. Over the years, chelator agents such as sodium citrate have gained favorability as a viable option to unfractionated heparin. Through calcium chelation, sodium citrate at a concentration of 4% suppresses blood coagulation within the catheter lumen. Sodium citrate has also been shown to be safe at this concentration even in the case of lock leakage.<sup>12</sup> We selected 4% sodium citrate for our evaluation because of its safety profile and the availability of a commercial formulation.<sup>7</sup>

Even at low concentrations of 4%, sodium citrate may inhibit biofilm formation and bacterial growth but may not be able to eradicate preexisting organisms. Therefore, addition of antimicrobial agents is necessary to prevent or manage CRBSIs. Vancomycin and low-dose gentamicin catheter

lock solutions have been reported in the literature.<sup>8,13</sup> Although data are limited, ethanol added to a lock solution also appears to be a promising option. Ethanol is bactericidal by protein denaturation and active against a wide variety of organisms and concerns of resistance are limited. An effective ethanol concentration that inhibits bacterial growth has been debated as well as concerns of catheter deterioration with higher ethanol concentrations.<sup>14</sup> In addition to vancomycin and low-dose gentamicin, we evaluated ethanol at 40% since an admixture containing ethanol provides another option to reduce CRBSI.

In our study, the 6 admixture combinations of sodium citrate and vancomycin with ethanol or gentamicin in 4 different conditions were assessed for compatibility, stability, and antibiotic activity. The Infectious Diseases Society of America (IDSA) guidelines recommend changing catheter

**Table 4.** Antimicrobial Disk Diffusion Susceptibility Testing of Catheter Lock Solutions Under Different Storage Conditions at 72 Hours.

Sample and storage conditions	Percentage of baseline zones of inhibition		
	<i>Staphylococcus aureus</i> ATCC 25923	<i>S aureus</i> UT <sup>a</sup>	<i>Escherichia coli</i> ATCC 25922
Vancomycin 5 mg/mL			
25°C without light	102.0 ± 1.4	99.2 ± 2.7	NA
25°C with light	98.2 ± 1.6	99.4 ± 1.2	NA
37°C without light	98.7 ± 1.5	97.7 ± 2.2	NA
37°C with light	101.8 ± 1.6	98.4 ± 1.4	NA
Vancomycin 5 mg/mL with 40% ethanol			
25°C without light	95.8 ± 1.3	100.0 ± 2.4	NA
25°C with light	95.8 ± 1.4	98.8 ± 2.4	NA
37°C without light	95.8 ± 1.3	98.5 ± 3.7	NA
37°C with light	100.9 ± 1.6	98.4 ± 2.7	NA
Vancomycin 5 mg/mL with gentamicin 1 mg/mL			
25°C without light	99.6 ± 0.8	98.1 ± 1.6	99.0 ± 0.8
25°C with light	98.6 ± 1.4	98.1 ± 1.2	100.3 ± 1.3
37°C without light	96.3 ± 1.6	97.3 ± 0.3	100.7 ± 1.2
37°C with light	95.2 ± 0.3	98.1 ± 1.6	100.1 ± 0.9
Vancomycin 10 mg/mL			
25°C without light	100.9 ± 1.6	101.2 ± 1.4	NA
25°C with light	101.1 ± 1.7	100.8 ± 1.3	NA
37°C without light	96.8 ± 2.7	100.9 ± 2.8	NA
37°C with light	100.0 ± 0.5	101.0 ± 1.3	NA
Vancomycin 10 mg/mL with 40% ethanol			
25°C without light	102.0 ± 2.1	97.8 ± 2.9	NA
25°C with light	100.6 ± 1.6	99.5 ± 0.5	NA
37°C without light	99.7 ± 1.7	99.4 ± 0.2	NA
37°C with light	101.7 ± 2.9	99.4 ± 0.2	NA
Vancomycin 10 mg/mL with gentamicin 1 mg/mL			
25°C without light	103.5 ± 3.0	100.8 ± 1.4	100.8 ± 1.4
25°C with light	100.4 ± 0.6	102.5 ± 0.1	102.5 ± 0
37°C without light	101.7 ± 3.9	104.4 ± 1.3	104.4 ± 1.3
37°C with light	105.9 ± 0.3	102.5 ± 0.1	102.5 ± 0

Note. NA = not applicable.

<sup>a</sup>Clinical strain of *S aureus* that is resistant to gentamicin but susceptible to vancomycin.

lock solutions every 48 hours. However, patients receiving thrice weekly hemodialysis may require a longer dwell period to accommodate the extended (68-72 hours) time between dialysis sessions that routinely occurs at the end of each week.<sup>1</sup> Therefore, we decided to evaluate our catheter lock solutions over a 72-hour period.

In our study, all solutions containing 4% sodium citrate combined with vancomycin 5 or 10 mg/mL with ethanol (40% v/v) or gentamicin 1 mg/mL remained stable over 48 hours regardless of storage conditions. However, turbidity was noted at 72 hours in our sample of vancomycin 5 mg/mL and ethanol in 4% sodium citrate when stored at 25°C or 37°C with or without light. All other solutions remained clear over 72 hours.

We conducted preliminary testing of ethanol compatibility with 4% sodium citrate in the absence of the antimicrobial agents (vancomycin and gentamicin) to determine the

highest concentration of ethanol we could utilize for this study. Our assessment found compatibility and stability when sodium citrate and ethanol constitute equal parts or an equal percentage of total volume (40% v/v). When sodium citrate exceeded ethanol as a percentage of total volume (50% vs 40%, respectively), we observed turbidity at 72 hours but not at baseline.

This was consistent with the findings of our study. The solution that contained vancomycin 5 mg/mL and ethanol was composed by combining 40% of ethanol with 50% of sodium citrate (4% solution). In contrast, the solution of vancomycin 10 mg/mL and ethanol, where total volume was 40% ethanol, and was combined with 40% sodium citrate (4% solution), remained clear over 72 hours regardless of storage conditions. Turbidity may be attributed to incompatibility between the 40% of ethanol and the 50% of commercially available 4% sodium citrate in the lock solution.

Therefore, this evidence suggested that mixing of 40% v/v ethanol with 4% sodium citrate in volumes higher than 40% v/v should be used with caution.

Prior compatibility and stability studies by our group did not assess the antibiotic susceptibility of the catheter lock solutions.<sup>4,5</sup> In this study, we evaluated antimicrobial activity of each admixture under 4 different conditions at baseline and at 72 hours. After 72 hours, antimicrobial activity ranged from 95% to 106% of the baseline zones of inhibition. These results support chemical stability testing that produced mean vancomycin and gentamicin concentrations that ranged between 95% and 105% of initial concentrations after 72 hours. Although we studied each admixture under different conditions, a limitation of this study was that we were not able to account for variables that may occur in a patient's daily activity such as body movement and variations in body temperature. Further evaluation of these admixtures in patients may be necessary to account for these variables.

## Conclusion

This study evaluated the in vitro physical stability, chemical compatibility, and antimicrobial susceptibility for the combination of sodium citrate and vancomycin with either ethanol or gentamicin. All solution containing sodium citrate 4% combined with vancomycin 5 or 10 mg/mL with ethanol (40% v/v) or gentamicin 1 mg/mL remained stable over 48 hours when stored in 25°C or 37°C with or without light. At 72 hours, vancomycin (5 mg/mL) and ethanol (40% v/v) in a 4% sodium citrate solution stored at 25°C with and without light, and at 37°C with and without light, became slightly turbid which we defined as incompatible for that time point. All other solution combinations under each of the 4 conditions maintained their compatibility, stability, and efficacy for 72 hours.

## Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

## Funding

The author(s) disclosed receipt of the following financial support for research, authorship, and/or publication of this article: The authors are grateful for the support of this research provided by the Department of Pharmacy Practice, University of Toledo College of Pharmacy & Pharmaceutical Sciences.

## References

1. Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular

- catheter-related infection: 2009 update by the Infectious Diseases Society of America. *Clin Infect Dis*. 2009;49:1-45. doi:10.1086/599376.
2. O'Grady NP, Alexander M, Burns LA, et al. Guidelines for the prevention of intravascular catheter-related infections. *Clin Infect Dis*. 2011;52:e162-e193. doi:10.1093/cid/cir257.
3. Wang Y, Ivany JN, Perkovic V, Gallagher MP, Woodward M, Jardine MJ. Anticoagulants and antiplatelet agents for preventing central venous haemodialysis catheter malfunction in patients with end-stage kidney disease. *Cochrane Database Syst Rev*. 2016;4:CD009631. doi:10.1002/14651858.CD009631.pub2.
4. Martha C, Boddu SH, Churchwell MD. Physical compatibility of sodium citrate with alcohol and cefepime. *Am J Health Syst Pharm*. 2013;70:932, 937. doi:10.2146/ajhp120499.
5. Dotson B, Lynn S, Savakis K, Churchwell MD. Physical compatibility of 4% sodium citrate with selected antimicrobial agents. *Am J Health Syst Pharm*. 2010;67:1195-1198. doi:10.2146/ajhp090505.
6. LaPlante KL, Woodmansee S, Mermel LA. Compatibility and stability of telavancin and vancomycin in heparin or sodium citrate lock solutions. *Am J Health Syst Pharm*. 2012;69:1405-1409. doi:10.2146/ajhp110256.
7. Yon CK, Low CL. Sodium citrate 4% versus heparin as a lock solution in hemodialysis patients with central venous catheters. *Am J Health Syst Pharm*. 2013;70:131-136. doi:10.2146/ajhp120300.
8. Moore CL, Besarab A, Ajluni M, et al. Comparative effectiveness of two catheter locking solutions to reduce catheter-related bloodstream infection in hemodialysis patients. *Clin J Am Soc Nephrol*. 2014;9:1232-1239. doi:10.2215/CJN.11291113.
9. Vercaigne LM, Allan DR, Armstrong SW, Zacharias JM, Miller LM. An ethanol/sodium citrate locking solution compared to heparin to prevent hemodialysis catheter-related infections: a randomized pilot study. *J Vasc Access*. 2016;17:55-62. doi:10.5301/jva.5000486.
10. Srilatha D, Nasare M, Nagasandhya B, Prasad V, Diwan P. Development and validation of UV spectrophotometric method for simultaneous estimation of hesperidin and diosmin in the pharmaceutical dosage form. *ISRN Spect*. 2013;2013:534830.
11. Clinical and Laboratory Standards Institute. *Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard*. 11th ed., CLSI document M02-A11. Wayne, PA: Clinical and Laboratory Standards Institute; 2012.
12. Zhao Y, Li Z, Zhang L, et al. Citrate versus heparin lock for hemodialysis catheters: a systematic review and meta-analysis of randomized controlled trials. *Am J Kidney Dis*. 2014;63:479-490. doi:10.1053/j.ajkd.2013.08.016.
13. Peterson WJ, Maya ID, Carlton D, Estrada E, Allon M. Treatment of dialysis catheter-related Enterococcus bacteremia with an antibiotic lock: a quality improvement report. *Am J Kidney Dis*. 2009;53:107-111. doi:10.1053/j.ajkd.2008.06.033.
14. Vercaigne LM, Takla TA, Raghavan J. Long-term effect of an ethanol/sodium citrate locking solution on the mechanical properties of hemodialysis catheters. *J Vasc Access*. 2010;11:12-16.